A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial

OBJECTIVES: Primary Objective • To evaluate the effect of ravulizumab, a long-acting complement (C5) inhibitor plus best supportive care (BSC) compared with BSC alone on the survival of patients with COVID-19. Secondary Objectives • Number of days free of mechanical ventilation at Day 29 • Duration...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Keisha, Pace, Amy, Ortiz, Stephan, Kazani, Shamsah, Rottinghaus, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355517/
https://www.ncbi.nlm.nih.gov/pubmed/32660611
http://dx.doi.org/10.1186/s13063-020-04548-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355517/
https://www.ncbi.nlm.nih.gov/pubmed/32660611
http://dx.doi.org/10.1186/s13063-020-04548-z

Ejemplares similares